Patients with non-Hodgkin lymphoma receiving treosulfan and fludarabine as reduced-intensity conditioning

被引：0
|
作者：
Schmitt, M. [1 ]
Trenschel, R. [2 ]
Sayer, H. G. [3 ]
Schneider, C. [1 ]
Glass, A. [4 ]
Hilgendorf, I. [1 ]
Treschl, A. [3 ]
Junghanss, C. [1 ]
Borchert, K. [1 ]
Koenigsmann, M.
Casper, J. [5 ]
Beelen, D. W. [2 ]
Freund, M. [1 ]
Kahl, C. [6 ]
机构：
[1] Univ Rostock, Dept Internal Med 3, Rostock, Germany
[2] Univ Essen Gesamthsch, Dept Internal Med, Essen, Germany
[3] Univ Jena, Dept Internal Med, Jena, Germany
[4] Univ Rostock, Inst Biostat & Informat Med & Ageing Res, Rostock, Germany
[5] Klinikum Oldenburg, Transplant Unit, Oldenburg, Germany
[6] Klinikum Magdeburg, Dept Hematol & Oncol, Magdeburg, Germany
来源：
ONKOLOGIE | 2011年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：299 / 300
页数：2
相关论文
共 50 条
  • [1] Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma
    Schmitt, Michael
    Trenschel, Rudolf
    Sayer, Herbert G.
    Schneider, Catarina
    Glass, Aenne
    Hilgendorf, Inken
    Treschl, Anne
    Junghanss, Christian
    Borchert, Kersten
    Koenigsmann, Michael
    Casper, Jochen
    Beelen, Dietrich W.
    Freund, Mathias
    Kahl, Christoph
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (05) : 773 - 782
  • [2] Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma (NHL)
    Schmitt, M.
    Sayer, H. G.
    Hilgendorf, I
    Treschl, A.
    Junghanss, C.
    Borchert, K.
    Koenigsmann, M.
    Casper, J.
    Freund, M.
    Kahl, C.
    ONKOLOGIE, 2010, 33 : 164 - 164
  • [3] Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin's lymphoma
    Schmitt, M.
    Trenschel, R.
    Sayer, H. G.
    Hilgendorf, I.
    Treschl, A.
    Glass, A.
    Junghanss, C.
    Borchert, K.
    Koenigsmann, M.
    Casper, J.
    Beelen, D. W.
    Freund, M.
    Kahl, C.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S247 - S247
  • [4] Conditioning with Treosulfan and Fludarabine for Patients with Refractory or Relapsed Non-Hodgkin Lymphoma (NHL)
    Schmitt, Michael
    Trenschel, Rudolf
    Sayer, Herbert G.
    Schneider, Catarina
    Glass, Aenne
    Hilgendorf, Inken
    Treschl, Anne
    Junghanss, Christian
    Borchert, Kersten
    Koenigsmann, Michael
    Casper, Jochen
    Beelen, Dietrich
    Freund, Mathias
    Kahl, Christoph
    BLOOD, 2011, 118 (21) : 1753 - 1753
  • [5] Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: Importance of histology for outcome
    Armand, Philippe
    Kim, Haesook T.
    Ho, Vincent T.
    Cutler, Corey S.
    Koreth, John
    Antin, Joseph H.
    LaCasce, Ann S.
    Jacobsen, Eric D.
    Fisher, David C.
    Brown, Jennifer R.
    Canellos, George P.
    Freedman, Arnold S.
    Soiffer, Rohert J.
    Alyea, Edwin P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (04) : 418 - 425
  • [6] Reduced-intensity conditioning allogeneic stem cell transplantation for patients with refractory or relapsed non-Hodgkin lymphoma
    De Lavallade, H.
    Bouabdallah, R.
    Faucher, C.
    Furst, S.
    El Cheikh, J.
    Vey, N.
    Stoppa, A. M.
    Sainty, D.
    Arnoulet, C.
    Xerri, L.
    Cassier, P.
    Gastaut, J. A.
    Blaise, D.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S149 - S149
  • [7] Reduced-intensity conditioning with fludarabine/busulfan versus fludarabine/low-dose melphalan in patients with non-Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantation
    Kamijo, Kimimori
    Shimomura, Yoshimitsu
    Kim, Sung-Won
    Ohigashi, Hiroyuki
    Ishikawa, Jun
    Eto, Tetsuya
    Hiramoto, Nobuhiro
    Mizuno, Ishikazu
    Iida, Shinsuke
    Ueda, Yasunori
    Matsuoka, Ken-ichi
    Yakushijin, Kimikazu
    Mori, Yasuo
    Onizuka, Makoto
    Fukuda, Takahiro
    Atsuta, Yoshiko
    Kako, Shinichi
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 1097 - 1107
  • [8] Reduced-Intensity Conditioning with Fludarabine/Busulfan Versus Fludarabine/Low-Dose Melphalan in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
    Kamijo, Kimimori
    Shimomura, Yoshimitsu
    Kim, Sung-Won
    Ara, Takahide
    Ishikawa, Jun
    Eto, Tetsuya
    Hiramoto, Nobuhiro
    Mizuno, Ishikazu
    Kusumoto, Shigeru
    Ueda, Yasunori
    Matsuoka, Ken-ichi
    Onizuka, Makoto
    Fukuda, Takahiro
    Atsuta, Yoshiko
    Kondo, Eisei
    BLOOD, 2022, 140 : 2393 - 2394
  • [9] Reduced-intensity conditioning allogeneic transplant in patients with aggressive non-Hodgkin lymphoma:: results of a prospective multicentre trial
    Martino, R
    Mateos, M
    Urbano, A
    León, A
    Odriozola, J
    Ribera, J
    Valcarcel, D
    Sarrá, J
    Vázquez, L
    Sureda, A
    Sierra, J
    San Miguel, J
    BONE MARROW TRANSPLANTATION, 2004, 33 : S110 - S110
  • [10] Reduced-intensity conditioning allogeneic transplant in patients with indolent non-Hodgkin lymphoma:: result of a prospective multicentre trial
    Caballero, D
    Martino, R
    Mateos, M
    Urbano, A
    Rubio, V
    Odriozola, J
    Ribera, J
    Sarrá, J
    Valcarcel, D
    Cañizo, M
    Moraleda, JM
    Sureda, A
    Sierra, J
    San Miguel, J
    BONE MARROW TRANSPLANTATION, 2004, 33 : S113 - S114
12345